RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA
Clinical trials for RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug enters first human trial for Tough-to-Treat leukemias
Disease control Recruiting nowThis is a first-in-human study to find a safe dose and understand the side effects of an experimental drug called TAK-243. It is for adults with acute myeloid leukemia or myelodysplastic syndromes that have returned or not responded to prior treatments. The drug is given by IV an…
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Apr 01, 2026 14:42 UTC
-
New hope for tough blood cancers: first human trial begins
Disease control Recruiting nowThis is a first-in-human study to find a safe dose of a new drug called cirtuvivint for patients with advanced forms of blood cancer. The trial will test cirtuvivint by itself in patients whose cancer has returned or resisted treatment, and also test it combined with an existing …
Matched conditions: RECURRENT MYELODYSPLASTIC SYNDROME/ACUTE MYELOID LEUKEMIA
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Mar 23, 2026 15:18 UTC